ArticlePloS one2026
First report of extended-spectrum beta lactamase (ESBL) and carbapenemase-producing MDR Klebsiella pneumoniae from Fuchka.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biofilm, virulence, and ESBL-mediated resistance: unmaskingMicrobiology spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-spectrum beta-lactamase (ESBL) and Carbapenemase-producing Gram-negative bacteria, particularly Klebsiella pneumoniae (ESBL-KP and CP-KP), in the food supply chain, poses a significant public health threat. Ready to eat (RTE) street foods, especially fuchka, a highly popular snack in Bangladesh, India and Southeast Asia, represents a critical breach in food safety. This study investigated the multidrug resistance (MDR) patterns of K. pneumoniae isolated from fuchka with an emphasis on phenotypic and genotypic detection of ESBL-KP and CP-KP. A total of 60 samples were collected from 15 fuchka selling points. K. pneumoniae was isolated and identified via staining, cultural methods, PCR and MALDI-ToF-MS biotyper. Antibiotic susceptibility test (AST) was accomplished using disk diffusion method, phenotypic ESBL producers was detected by combined disk test (CDT) and PCR was used to detect resistance determinant. Thirty K. pneumoniae isolates were confirmed by PCR and MALDI-ToF-MS. All showed resistance to amoxicillin and cefuroxime (100%), while most were sensitive to cefepime (96.7%), norfloxacin (96.7%), imipenem (93.3%) and meropenem (83.3%). All the isolates were MDR, with multiple-antibiotic resistance (MAR) index values ranged from 0.28 to 0.64. CDT confirmed 28 ESBL producers. Among ESBL-producing genes blaTEM, was most prevalent (64%), followed by blaSHV, blaOXA-1, blaCTX-M1, blaCTX-M3. Among carbapenem-resistant genes, blaBIC was most common (46%), while blaVIM was absent. Moreover, other resistance determinants (aadA1, aac3IV was most prevalent (40%) but aadA1, qnrA were not detected. The presence of multidrug-resistant, ESBL- and carbapenemase-producing K. pneumoniae in fuchka represents a critical threat to public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.